NOVOZYMES, GREAT GREEN PLAY BUT WAIT (REDUCE; -9% DOWNSIDE)
20/11/20 -"Novozymes (Reduce, Denmark) is a classic example of a ‘good company at an unattractive price’. We were cautiously optimistic on this Denmark-based enzyme market leader (48% share) when we teased ..."
Pages
62
Language
English
Published on
20/11/20
You may also be interested by these reports :
24/08/26
Q2 profitability beat expectations; however, the top line lagged consensus. The quarterly growth was driven by strong performance in LatAm, Animal ...
21/08/26
The H1 profitability surpassed consensus, though sales matched expectations. The Branded segment was the sole driver of sales growth in H1, though ...
21/08/26
Siegfried delivered a strong set of results in 1H26. Net sales grew by +2.2% YoY (+4.8% in LC), largely supported by the additional revenues ...
21/08/26
Moderna’s mRNA cancer vaccine combined with Merck’s Keytruda does look like a game changer for the wider pharma industry. It looks like a decisive ...